tigilanol tiglate

Small moleculeexperimental

Clinical trial activity

4 trials · 6 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0

Earliest trial started May 7, 2021 (NCT04834973)

Timeline

2020s

  1. Jan 1, 2021

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2022

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

C/C=C(\C)C(=O)O[C@@H]1[C@@H](C)[C@@]2(O)[C@H]([C@@H]3C(C)(C)[C@]13OC(=O)[C@@H](C)CC)[C@@H]1O[C@]1(CO)[C@@H](O)[C@]1(O)C(=O)C(C)=C[C@H]12
Mol. weight
562.66 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05755113Phase 2Apr 13, 2023Memorial Sloan-Kettering Cancer Center, QBiotics Group Limited
NCT05608876Phase 2Nov 30, 2022QBiotics Group Limited
NCT05234437Phase 2Mar 9, 2022Cairns Hospital, Melanoma Institute Australia, Princess Alexandra Hospital, QBiotics Group Limited
NCT04834973Phase 1/Phase 2 (Phase 2)May 7, 2021Melanoma Institute Australia, Merck, QBiotics Group Limited
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (6)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
QBiotics Group LimitedFor profit4412021
Melanoma Institute AustraliaAcademic/Hospital2012021
Cairns HospitalAcademic/Hospital1012022
Memorial Sloan-Kettering Cancer CenterAcademic/Hospital1012023
MerckFor profit1012021
Princess Alexandra HospitalAcademic/Hospital1012022
6 organizations
Page 1 / 1